You just read:

Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

News provided by

Immunic, Inc.

Oct 10, 2019, 16:01 ET